Is SYRE up or down today?
SYRE is up 2.13% today, last at 90.60. This stock moved +2.13% versus the prior close.
SYRE · SYRE
SYRE (SYRE) is trading at 90.60, up 2.13% on the session. SYRE carries a 14-day RSI of 43, and trades below its 50-day average. Over the past month it is down 12.96%.
Leading the coverage: “SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus” (Google News Company, 4d ago). SYRE is +0.79% since story.
SYRE trades on a trailing P/E of 34.0 and is running 11.90% behind the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
SYRE is up 2.13% today, last at 90.60. This stock moved +2.13% versus the prior close.
Leading the coverage: “SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus” (Google News Company, 4d ago). SYRE is +0.79% since story. Dominant story: Spyre Therapeutics (SYRE) Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis - simplywall.st (1 source, neutral) RSI is 43 — leaning bearish Price below 50-day average — short-term weakness Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Mar 2026 – Sep 2026 (125 days) · Drag or scroll left for earlier dates
Spyre Therapeutics (SYRE) Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis - simplywall.st
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus